In contrast, one may hypothesize that low to normal responders (e.g. those with AMH ≤ 15 pmol/L) treated with individualized follitropin delta in a long GnRH agonist protocol may have a higher ovarian response than in a GnRH antagonist protocol, whereas the risk of OHSS may not be increased due to the individualized FSH dosing. Here, BRD2 is linked to ovarian hyperstimulation syndrome.